BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,037 filers reported holding BAXTER INTL INC in Q1 2015. The put-call ratio across all filers is 0.65 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2018 | $202,000 | -47.7% | 3,100 | -48.0% | 0.04% | -48.1% |
Q4 2017 | $386,000 | -18.2% | 5,965 | -20.7% | 0.08% | -22.9% |
Q3 2017 | $472,000 | -31.5% | 7,520 | -33.9% | 0.10% | -34.0% |
Q2 2017 | $689,000 | +1.5% | 11,375 | -13.1% | 0.16% | 0.0% |
Q1 2017 | $679,000 | +6.8% | 13,089 | -8.8% | 0.16% | +0.6% |
Q4 2016 | $636,000 | -14.7% | 14,349 | -8.5% | 0.16% | -17.3% |
Q3 2016 | $746,000 | -4.4% | 15,675 | -9.1% | 0.19% | -7.7% |
Q2 2016 | $780,000 | -3.5% | 17,241 | -12.4% | 0.21% | -6.3% |
Q1 2016 | $808,000 | -5.3% | 19,676 | -12.0% | 0.22% | -7.5% |
Q4 2015 | $853,000 | +10.5% | 22,356 | -4.9% | 0.24% | +4.8% |
Q3 2015 | $772,000 | -47.9% | 23,498 | +12.0% | 0.23% | -45.1% |
Q2 2015 | $1,481,000 | +9.1% | 20,986 | +5.9% | 0.42% | +6.1% |
Q1 2015 | $1,358,000 | -4.4% | 19,818 | +2.3% | 0.39% | -7.6% |
Q4 2014 | $1,420,000 | +7.5% | 19,376 | +5.3% | 0.42% | +2.9% |
Q3 2014 | $1,321,000 | +10.5% | 18,406 | +11.3% | 0.41% | +9.0% |
Q2 2014 | $1,196,000 | +59.3% | 16,538 | +62.1% | 0.38% | +49.6% |
Q1 2014 | $751,000 | +13.3% | 10,203 | +7.1% | 0.25% | +8.2% |
Q4 2013 | $663,000 | +37.8% | 9,528 | +31.4% | 0.23% | +19.5% |
Q3 2013 | $481,000 | -1.0% | 7,253 | +3.4% | 0.20% | -2.0% |
Q2 2013 | $486,000 | – | 7,014 | – | 0.20% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tavio Capital LLC | 68,405 | $5,890,000 | 7.81% |
Iron Triangle Partners LP | 330,000 | $28,413,000 | 7.16% |
Veritas Asset Management LLP | 8,942,428 | $769,943,000 | 5.64% |
TSFG, LLC | 93,405 | $8,042,000 | 5.31% |
GENERATION INVESTMENT MANAGEMENT LLP | 10,606,094 | $913,185,000 | 5.27% |
Third Point | 4,000,000 | $344,400,000 | 4.72% |
Avidity Partners Management LP | 800,900 | $68,957,000 | 4.42% |
Palmer Knight Co | 62,275 | $5,362,000 | 4.17% |
Eos Focused Equity Management, L.P. | 36,786 | $3,167,000 | 3.70% |
Dundas Partners LLP | 196,133 | $16,887,000 | 3.69% |